Latest

Benitec reports fiscal 2026 results, updates BB-301 trial progress and FDA meeting

All six low-dose patients finished 12-month follow-up, high-dose cohort is fully enrolled and treated, and Benitec plans a pivotal trial start in mid-2027.

SEC filing